A trading fund aiming to profit from the volatility and uncertainty surrounding the IMO’s new low sulphur regulations has made a disastrous start.
The fund, part of Oslo-based drug maker Vistin Pharma, has racked up losses of NOK 101.3m ($12m) from trading bunker fuel derivatives.
